The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Essent continues to broaden its highly characterized, low passage primary cell catalog
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Recommendation is based on pivotal data from the phase III POLARIX study
Subscribe To Our Newsletter & Stay Updated
